Abstract:Background: Identifying the high recurrence group of patients with early-stage papillary thyroid cancer (PTC) is the greatest challenge in the management of this disease. It has been noted that B-type Rafkinase (BRAF) V600E mutation and programmed death ligand 1 (PD-L1) are associated in PTC and highly expressed in PTC, correlating in PTC as potential prognostic biomarkers. However, whether they can be used to predict the aggressiveness and recurrence of early PTC remains unclear. Methods: Clinicopathological data of 137 patients with early PTC [tumor-node-metastasis (TNM) stage I-II] who underwent surgery in Zhejiang Cancer Hospital between 2008 and 2010 were retrospectively analyzed. BRAF(V600E) mutation and PD-L1 was detected by immunohistochemistry. The median follow-up time was 136 months (interquartile range 5.8). The presence of tumor confirmed by imaging or pathology or lymph node metastasis was considered as tumor recurrence. The association of both alone and in combination with clinicopathological features and recurrence was statistically analyzed respectively. The risk of recurrence was assessed using Cox regression models. Results: Most of the 137 early PTC were female (78.1%). The mean age was 43.2 +/- 12.1 years. The median tumor size was 1.4 cm; 14 patients developed recurrence during follow-up period; 56 patients (40.9%) were detected positive for BRAF(V600E) mutation; 76 patients (55.5%) were detected positive for PD-L1. Patients with both BRAF(V600E) mutation and PD-L1 expression had larger tumors (P=0.038), were more likely to have extrathyroidal invasion (P=0.045), and had a lower rate of cervical lymph node metastasis (P=0.046). The recurrence rate was 17.5% (7/40) in patients with BRAF(V600E) mutation and PD-L1 double expression compared to 8.9% (4/45) in patients with BRAF(V600E) mutation and PD-L1 double negative [hazard ratio (HR) =1.267; 95% CI: 0.841-1.909; P=0.257]. Survival curves showed flatter recurrence-free survival (RFS) curves in positive BRAF(V600E) mutation only and PD-L1 expression only, whereas decreased sharply in positive expression of both BRAF(V600E) mutation and PD-L1; however, the differences were not significant (P>0.05). Conclusions: The combination of BRAF(V600E) mutation and PD-L1 to identify group at higher risk of recurrence in early PTC has insufficient clinical evidence and should be used with caution in the clinical management of PTC.

Evaluation of epithelial-to-mesenchymal transition and Ki-67 index in aggressive papillary thyroid cancer

Clinicopathological Significance And Prognostic Value Of Nkx2.2 Expression In Papillary Thyroid Carcinoma

Immunohistochemistry related to the diagnosis and metastasis of papillary thyroid carcinoma

Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma

BRAFV600E mutation and NIS expression in papillary thyroid carcinomas

Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary Thyroid Cancer

Cytokeratin 19, Thyroperoxidase, HBME-1 and Galectin-3 in Evaluation of Aggressive Behavior of Papillary Thyroid Carcinoma.

Conventional Ultrasound, Immunohistochemical Factors and BRAFV600E Mutation in Predicting Central Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma.

Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.

Accuracy of World Health Organisation‐grade parameters (necrosis and mitotic activity) and foci of vascular invasion in predicting prognosis of papillary thyroid carcinoma. A case–control validation study

Morphological changes, gene expression and prognosis in papillary thyroid carcinoma

The Involvement of CXCR7 in Modulating the Progression of Papillary Thyroid Carcinoma.

The Clinicopathological Significance of Ki67 in Papillary Thyroid Carcinoma: a Suitable Indicator?

Combined expression of the <i>BRAFV600E</i> mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence-a retrospective cohort study

Clinical significance of multi-genic assay in identifying aggressive papillary thyroid carcinoma

Comprehensive Immunohistochemical Analysis of Epithelial-Mesenchymal Transition Biomarkers in the Invasive Micropapillary Cancer of the Breast

Expression of PUMA in Papillary Thyroid Carcinoma and Its Role in Inducing Apoptosis

The Protein Expression and Clinical Significance of Metastasis-Associated Gene 1, Matrix Metalloproteinase-2 and Coiled-Coil Domain Containing 67 in Papillary Thyroid Carcinoma

PD-L1 and PD-1 Expression Are Correlated with Distinctive Clinicopathological Features in Papillary Thyroid Carcinoma

Expression and clinical significance of Ki67 in medullary thyroid carcinoma

The Protein Expression and Clinical Significance of Coiled-Coil Domain Containing 67 and B Cell Lymphoma/leukemia-2 in Papillary Thyroid Carcinoma